Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: cancer
Opinion: Blood tests for cancer detection aren’t yet ready for prime time
Multi-cancer early detection tests (MCEDs), sometimes called liquid biopsy tests, are a new method of…
Listen: Psychedelics at the FDA, ASCO recap, & MorphoSys update
How did advisers react to the first psychedelic therapy to go before the Food and…
ASCO Takeaways: Winners, snoozers, the China question and the art of cancer care
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
.jpg)
Operation Warp Speed but for rare disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug
CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly…
STAT+: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial
CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with…
Can AstraZeneca make good on its promise?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Delfi Diagnostics announces key data, study design for its liquid biopsy test
CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen…
STAT+: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
Palliative care for cancer patients is found to be as effective given virtually as in person
CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well…
STAT+: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
In patients with stage 3 lung cancer where a particular genetic mutation is present in…
STAT+: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment
CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a…
STAT+: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market
LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew…
STAT+: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
.jpg)
STAT+: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today…
STAT+: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone
CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers…
STAT+: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment
CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor…
How can hospitals boost cancer screening rates? Researchers report that an AI helped
CHICAGO — People can be mightily reluctant to get a colonoscopy for reasons like cost,…
The surprising outperformance of a new drug against existing competitors, and other biotech updates
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Biotech’s most interesting fundraisings from the last week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: ASCO preview: a promising solid tumor CAR-T, an AI patient navigator, and improving palliative care
Thousands of cancer researchers and clinicians are flocking to Chicago for the American Society of…
More tumult at BIO amid the company’s fourth CEO in four years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Embrace an Anti-Inflammation Diet and Enjoy Better Health and Well-Being
Anti-inflammatory diets focus on whole, nutrient dense foods, while minimizing or eliminating processed foods, refined…
Frontline: Breast cancer recurrence; benefits from a daily walk; gender discrimination
Adding a Drug to Hormone Therapy Reduced the Risk of Breast Cancer Recurrence A new…
Consider the Pros and Cons of Multicancer Early Detection Tests
Approximately 70 percent of cancer-related deaths stem from cancers without established screening tests, according to…
Seek Shade and Use Sunscreen Daily to Shield Yourself from Harmful Rays
Protecting your skin from the sun reduces your risk of skin cancer, helps prevent new…
STAT+: FDA advisers endorse Guardant Health’s colon cancer screening test
An independent panel of advisers to the Food and Drug Administration recommended the agency approve…
STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some…
The HPV vaccine prevents cancer in men, too. Why do so few people get it?
You’d think if there were a vaccine that would prevent tens of thousands of cases…
STAT+: Setting the table: What to expect at this year’s ASCO meeting
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: At a flashy new research hub, AstraZeneca lays out ambitious growth goals
CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious…
Black Americans’ risk for breast cancer gains clarity in analysis of 40,000 genomes
Hundreds of genetic variants can nudge someone’s risk of breast cancer up or down or…
STAT+: PDS Biotech’s survival benefit is absurdly overstated
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S.
Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday…
Leqembi gets closer to being offered as an injection
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug
A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to…
After decades fighting Big Tobacco, Cliff Douglas now leads a foundation funded by his former adversaries
“Does it trouble you to answer that question?” one of New York’s highest paid attorneys…
Opinion: First Opinion essay on colorectal cancer screening: letter and response
To encourage robust, good-faith discussion about difficult issues, STAT publishes selected Letters to the Editor…
Exact Sciences’ stock tumbles amid worries cancer detection firm’s growth may slow
Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection…
STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available
In the latest bid to widen access to medicines, a nonprofit is sending technology and…
Meet the scientist sending tumors into space
What happens when you catapult cancer into space? Or shoot stem cells toward the stars?…
Opinion: Readers respond to funding academic medical centers, the ‘residency research arms race,’ and more
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
Opinion: Why isn’t there agreement on when women need to start getting mammograms?
If, after reading the latest recommendation on breast cancer screening by the United States Preventive…
STAT+: BridgeBio spins out oncology company as it focuses on heart drug
BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it…
STAT+: Novartis extends radiopharma plans with $1 billion acquisition
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even…
STAT+: Biological clocks could be the key to longer, healthier lives. But scientists don’t yet agree on what ‘aging’ is
It’s no secret that a lucky few seem to glide into old age, the years…
Opinion: Colorectal cancer is increasing among young people. It’s time to boost research on it
I am not writing here to talk about my husband, Chadwick Boseman, who died far…
With younger women getting breast cancer, national panel lowers mammogram screening age to 40
A national advisory panel significantly lowered the age recommendations for screening mammography on Tuesday, saying…